Here are three things to know:
1. The round included $3.9 million in equity and a $2 million credit facility.
2. Bone Biologics will use the proceeds for working capital, protein development, regulatory and clinical expenses and to repay $600,000 in debt.
3. The company is developing the recombinant human protein growth factor NELL-1 bone graft substitute for spinal fusion.
More articles on biologics:
Viscogliosi Brothers to purchase Bioventus’ BMP development program: 5 insights
3 things to know about Ortho RTi
23 developments in spine & orthopedic biologics research in 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
